A Phase 1 interventional study of ABBV-547 and ABBV-547 Placebo in Healthy Volunteer and Psoriasis, sponsored by AbbVie. Active, not recruiting at 20 sites in 2 countries. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by AbbVie · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 79 studies in Psoriasis by AbbVie — 2 open to participants now, 6 under way, 1 of them phase 3. Psoriasis · AbbVie.
Among the 79 studies in Psoriasis by AbbVie, this one is the 28th largest by planned enrollment of the 48 interventional ones that give a count, is one of 2 that started in 2025, is one of 6 in phase 1, and was the 78th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →2 of the 79 studies in Psoriasis by AbbVie are open now, in 8 countries. Recruiting first, the newest first:
AbbVie · Sites in Canada, Czechia, France and 5 more countries
Ages 18+
AbbVie
Ages 18–75
By country, each count listing its studies:
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
79 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 6 · Phase 3 31 · Phase 4 5
First in 2005; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 142 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 166 across the 48 interventional studies, 246 across the 31 observational. Of the 71 that completed or were terminated, 42 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
1 of the studies in Psoriasis by AbbVie that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06247319AbbVieStudy to Evaluate the Effectiveness of Risankizumab in Participants With a Recent Diagnosis of Moderate Plaque Psoriasis in a Real-life Setting in Greece | 2027-10 |
Add it to your calendar (.ics) → With an account.
Among the 79 studies in Psoriasis by AbbVie, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess how safe, effective, and tolerable ABBV-547 is in adult participants in the United States and Japan.
There will be 2 parts to this study. In Part 1, participants are placed in one of 7 groups where they will receive ABBV-547 at different doses or placebo. There is a 1 in 4 chance participants will receive placebo. In Part 2, participants are placed in one of 4 groups where they will receive ABBV-547 at different doses or placebo. There is a 1 in 7 chance participants will receive placebo. Group 11 is the only group that will receive multiple doses. Approximately 142 adult participants will be enrolled at approximately 21 sites in the United States and Japan.
Participants will be administered one dose or multiple doses of ABBV-547 or placebo.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive either ABBV-547 or placebo.
Drug: ABBV-547 · Drug: ABBV-547 Placebo
Participants will receive either ABBV-547 or placebo.
Drug: ABBV-547 · Drug: ABBV-547 Placebo
Participants will receive either ABBV-547 or placebo.
Drug: ABBV-547 · Drug: ABBV-547 Placebo
Participants will receive either ABBV-547 or placebo.
Drug: ABBV-547 · Drug: ABBV-547 Placebo
Participants will receive either ABBV-547 or placebo.
Drug: ABBV-547 · Drug: ABBV-547 Placebo
Participants will receive either ABBV-547 or placebo.
Drug: ABBV-547 · Drug: ABBV-547 Placebo
Participants will receive either ABBV-547 or placebo.
Drug: ABBV-547 · Drug: ABBV-547 Placebo
Japanese participants will receive either ABBV-547 or placebo.
Drug: ABBV-547 · Drug: ABBV-547 Placebo
Han Chinese participants will receive either ABBV-547 or placebo.
Drug: ABBV-547 · Drug: ABBV-547 Placebo
Participants will receive either ABBV-547 or placebo.
Drug: ABBV-547 · Drug: ABBV-547 Placebo
Participants will receive either ABBV-547 or placebo.
Drug: ABBV-547 · Drug: ABBV-547 Placebo
Parental Administration
Parental Administration
Number of Participants with Adverse Events (AEs)
An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Time frame: Up to Approximately Day 365
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for May 2028, 30 months after the start.
Of 137 industry-sponsored phase 1 interventional studies under Psoriasis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's planned 30 months is above that.
Counting every sponsor, half of 155 studies reached it within 10 months; a quarter within 5 and three quarters within 17.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Aug 2027 → May 2028 and completion Aug 2027 → May 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.